Lucid Diagnostics将不再与PAVmed的财务报表合并

2024-09-17 15:33

PAVmed (NASDAQ:PAVM) on Monday said that as part of its efforts to regain compliance with Nasdaq's listing requirements, Lucid Diagnostics (NASDAQ:LUCD) will be de-consolidated from PAVmed's financial statements.
As a result, PAVmed will no longer report consolidated financials reflecting Lucid's operating losses.
PAVmed's holdings of Lucid common stock (LUCD) remain unchanged, and the value of these holdings will be reported going forward as an asset on its balance sheet, substantially increasing the company's stockholder's equity, PAVmed (PAVM) said.
"The deconsolidation was effectuated by changing the composition of PAVmed's board of directors, and as a result of it no longer controlling a majority of the voting interests in Lucid."
Efforts also include the appointment of seasoned biotech investor Sundeep Agrawal, M.D. to the board to replace departing directors.
The deconsolidation does not affect PAVmed's holdings of Lucid common stock, and PAVmed remains Lucid's largest shareholder. It is also the first in a series of steps that the company is seeking to take in order to regain compliance with the Nasdaq continued listing standards.
Source: Press Release

More on Lucid Diagnostics, PAVmed, etc.